NCT01238796View on ClinicalTrials.gov

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Kidney DiseasesEnd Stage Renal Disease
Interventions
DRUG

telavancin

Intravenous

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

37920

New Orleans Center for Clinical Research, Knoxville

55404

DaVita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY